article thumbnail

STAT+: Dreams of cancer vaccines are becoming more real. Here are 9 scientists making it happen 

STAT

Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at Mass General Cancer Center. Shadowed by the successes of other therapies, the field of cancer vaccines was “seemingly dying,” Sullivan said. Continue to STAT+ to read the full story…

Vaccines 363
article thumbnail

Opinion: I helped declare the U.S. measles-free in 2000. I’m dismayed by where we are now

STAT

I started my medical career in the early 1990s as a vaccine nihilist. I offered vaccines to my patients and was adherent to the routine schedules, but certainly did not go out of my way to encourage or cajole. I neglected to have my first child vaccinated against chickenpox; the scars are still present.

Vaccines 318
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Cancer vaccines gain momentum, after years of disappointing results

STAT

SAN DIEGO — Cancer vaccines have traveled a potholed road over the last decade. But as researchers from different companies and academic institutions presented promising early data at the American Association for Cancer Research annual meeting in San Diego this week, experts said there’s a collective feeling of turning a corner.

Vaccines 364
article thumbnail

RSV vaccines may be linked to small increased risk of developing Guillain-Barré syndrome, data suggest

STAT

The new vaccines that protect older adults against respiratory syncytial virus, or RSV, may be linked to a small increased risk of developing Guillain-Barré syndrome, new data from the Centers for Disease Control and Prevention and the Food and Drug Administration suggest. Read the rest…

Vaccines 360
article thumbnail

STAT+: Moderna says RSV vaccine worked, setting stage for competition with GSK and Pfizer

STAT

Moderna’s vaccine against the respiratory syncytial virus, or RSV, reduced the rate of lower respiratory disease in people over 60 in a Phase 3 trial, the company said Tuesday. The result will increase competition in a soon-to-be crowded market.

Vaccines 314
article thumbnail

Flu vaccine offering decent levels of protection this winter, new data show

STAT

Flu vaccine appears to be offering reasonable levels of protection this winter, with particularly strong levels in children, new data from the Centers for Disease Control and Prevention suggest. Read the rest…

Vaccines 303
article thumbnail

AstraZeneca showcases innovation in infectious disease protection at ESCMID Global 2025

LifeProNow

April 8, 2025: “AstraZeneca will share new data across its Vaccines & Immune Therapies portfolio at the 2025 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria, from 11-15 April 2025. There are millions of methicillin-resistant S.

Vaccines 130